BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28237404)

  • 21. Pharmacogenetics of immunosuppressants: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics (RNPGx).
    Woillard JB; Chouchana L; Picard N; Loriot MA;
    Therapie; 2017 Apr; 72(2):285-299. PubMed ID: 28318610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.
    Cavallari LH; Nutescu EA
    Clin Pharmacol Ther; 2014 Jul; 96(1):22-4. PubMed ID: 24942399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy].
    Kokh NV; Slepukhina AA; Tsvetovskaya GA; Lifshits GA
    Kardiologiia; 2015; 55(4):57-60. PubMed ID: 26502504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomics and adverse drug reactions: the case of statins.
    Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
    Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacogenomics of warfarin and clopidogrel.
    Shin J
    J Pharm Pract; 2012 Aug; 25(4):428-38. PubMed ID: 22674970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].
    Loriot MA; Beaune P
    Rev Prat; 2007 Jun; 57(12):1281-6. PubMed ID: 17717937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
    Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
    Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review.
    Raymond J; Imbert L; Cousin T; Duflot T; Varin R; Wils J; Lamoureux F
    J Pers Med; 2021 Jan; 11(1):. PubMed ID: 33440670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacogenetics of statin therapy: when the body aches, the mind will follow.
    Rossi JS; McLeod HL
    J Am Coll Cardiol; 2009 Oct; 54(17):1617-8. PubMed ID: 19833261
    [No Abstract]   [Full Text] [Related]  

  • 30. The importance of including African populations in pharmacogenetics studies of warfarin response.
    Dandara C; Ndadza A; Soko N
    Pharmacogenomics; 2022 Jan; 23(1):1-4. PubMed ID: 34821506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
    Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
    J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic predisposition to adverse drug reactions in the intensive care unit.
    Empey PE
    Crit Care Med; 2010 Jun; 38(6 Suppl):S106-16. PubMed ID: 20502164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update on efflux and uptake transporters as determinants of statin response.
    Rocha KCE; Pereira BMV; Rodrigues AC
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):613-624. PubMed ID: 29842801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of coumarinic oral anticoagulants.
    Manolopoulos VG; Ragia G; Tavridou A
    Pharmacogenomics; 2010 Apr; 11(4):493-6. PubMed ID: 20350128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translation of pharmacogenetics into clinically relevant testing modalities.
    Baudhuin LM; Langman LJ; O'Kane DJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):373-6. PubMed ID: 17851577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype frequencies of VKORC1 and CYP2C9 in native and Mestizo populations from Mexico, potential impact for coumarin dosing.
    Villegas-Torres B; Sánchez-Girón F; Jaramillo-Villafuerte K; Soberón X; Gonzalez-Covarrubias V
    Gene; 2015 Mar; 558(2):235-40. PubMed ID: 25560189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
    Baker WL; Chamberlin KW
    Clin Pharmacol Ther; 2014 Jul; 96(1):17-9. PubMed ID: 24942397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotype-based dosage of acenocoumarol in highly-sensitive geriatric patients.
    Lozano R; Franco ME; López L; Moneva JJ; Carrasco V; Pérez-Layo MA
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):206-10. PubMed ID: 25669612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the
    Kim CO; Oh ES; Kim H; Park MS
    Drug Des Devel Ther; 2017; 11():503-512. PubMed ID: 28260863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.